Agios Pharmaceuticals Inc. | Ownership
Companies that own Agios Pharmaceuticals Inc.
Fidelity Management & Research Co.
8,626,243
14.88%
45,232
0.07%
06/30/2018
Wellington Management Co. LLP
7,646,700
13.19%
-125,574
0.12%
06/30/2018
The Vanguard Group, Inc.
4,106,944
7.08%
141,858
0.01%
06/30/2018
T. Rowe Price Associates, Inc.
2,946,809
5.08%
-179,214
0.03%
06/30/2018
Capital Research & Management Co. (International Investors)
2,805,029
4.84%
-17,255
0.23%
06/30/2018
BlackRock Fund Advisors
2,612,149
4.5%
-39,288
0.01%
06/30/2018
Bellevue Asset Management AG
2,226,742
3.84%
-348,811
2.6%
06/30/2018
ClearBridge Investments LLC
1,506,642
2.6%
-21,766
0.1%
06/30/2018
SSgA Funds Management, Inc.
1,348,516
2.33%
-140,992
0.01%
06/30/2018
Lord, Abbett & Co. LLC
1,208,083
2.08%
163,737
0.25%
06/30/2018
| Address |
88 Sidney Street
Cambridge Massachusetts 02139
United States
|
|
Employees
|
- |
| Website |
http://www.agios.com |
| Updated |
07/08/2019 |
| Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. Its product candidates include IDHIFA, ivosidenib, AG-881, AG-348, and AG-270. |
